Sleep habits in the pathogenesis and management of diabesity
- PMID: 40452148
- PMCID: PMC12209523
- DOI: 10.1111/jdi.70075
Sleep habits in the pathogenesis and management of diabesity
Abstract
In parallel with the rising global epidemic of obesity and diabetes, termed "diabesity" to underscore the strong relationship between these two conditions, there has been a decreasing trend in the average sleep duration in many parts of the world. Sleep is an essential component of everyday life and plays a pivotal role in regulating energy metabolism and many other physiological functions. Updated guidelines include adequate sleep as one of the key elements of lifestyle therapy in diabetes management. From epidemiological studies, there are many researchers across the globe demonstrating a U-shaped relationship between sleep duration and glycemia, as well as more adverse clinical outcomes (notably cardiovascular events and mortality) with shorter sleep in people with diabetes. Sleep deprivation results in inflammation, neurohormonal dysregulation impacting on appetite control, hedonic pathways, and reward processing and eventually facilitates obesity and diabetes. While there is a wealth of evidence supporting the mechanistic links between short sleep duration, weight gain, and dysglycemia, the reasons why long sleepers have worse metabolic health remain obscure. Not only sleep duration matters, but circadian alignment and quality of sleep are also crucial in optimizing metabolic health. Recognizing the importance of promoting sleep hygiene via non-pharmacological strategies, such as sleep extension interventions and cognitive behavioral therapy, is attracting increasing clinical attention to prevent and manage people with diabesity.
Keywords: Cognitive behavioral therapy; Diabesity; Sleep extension therapy.
© 2025 The Author(s). Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
APSK has received research grants and/or speaker honoraria from Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli‐Lilly, Kyowa Kirin, Merck Serono, Merck Sharp & Dohme, Nestle, Novo‐Nordisk, Pfizer, Sanofi, and Zuellig Pharma. Other authors declared no conflict of interest associated with the contents of this manuscript.
Approval of the research protocol: N/A.
Informed consent: N/A.
Registry and the registration no. of the study/trial: N/A.
Animal studies: N/A.
Figures
References
-
- Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm ‐ 2020 executive Summary. Endocr Pract 2020; 26: 107–139. - PubMed
-
- WHO . Obesity and overweight.
-
- International Diabetes Federation . IDF Atlas, 10th edn. Brussels: International Diabetes Federation, 2021.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
